Astellas' Prosidion Subsidiary Sells Dipeptidyl Peptidase IV (DPP-IV) Patent Estate and Associated Royalty Interest to Royalty Pharma for USD 609 Million - MarketWatch
Links shared publicly online about this topic.
- 181total visits
Astellas' Prosidion Subsidiary Sells Dipeptidyl Peptidase IV (DPP-IV) Patent Estate and Associated Royalty Interest to Royalty Pharma for USD 609 Million - MarketWatch
View full resource at marketwatch.com
Tags: Diabetes, Type 2 Diabetes, Pharma
Most Recently Shared on June 30, 2011 at 11:58 am By:
Astellas subsidiary Prosidion sells DPP-IV inhibitor (for type 2 diabetes) patent estate to Royalty Pharma for $609m: http://t.co/9AmdbBP
preview
emailactivity.ecn5.com — “preview” View full resource at emailactivity.ecn5.com
Most Recently Shared on April 6, 2012 at 6:20 pm By:
PharmaLive Pharma and Health News
#FDA Panel Backs #Astellas Overactive Bladder Drug http://t.co/SZJYL0Kn #DailyAdvantage
Canadian Urological Association Partners with Astellas Pharma Canada, Inc. - Drugs.com MedNews
drugs.com — “Partnership establishes grant to advance urology research in Canada MARKHAM, ON, March 28, 2012 PRNewswire - The Canadian Urological Association (CUA) and Astel” View full resource at drugs.com
Most Recently Shared on March 28, 2012 at 5:02 pm By:
Drugs and Devices OW OW Health
Canadian Urological Association Partners with Astellas Pharma Canada, Inc.: Partnership establishes grant ... http://t.co/YW3g07NO #drug
Canadian Urological Association Partners with Astellas Pharma Canada, Inc. - Yahoo! Finance
finance.yahoo.com — “From Yahoo! Finance: Partnership establishes grant to advance urology research in CanadaMARKHAM, ON, March 28, 2012 /PRNewswire/ - The Canadian Urological Association (CUA) and Astellas Pharma Canada, Inc. have announced the ...” View full resource at finance.yahoo.com
Most Recently Shared on March 28, 2012 at 4:48 pm By:
Urology & Nephrology OW Health
Canadian Urological Association Partners with Astellas Pharma Canada, Inc.: Partnership establishes grant to adv... http://t.co/LQm8bBqn
2012 Voluntary Health Leadership Conference
nationalhealthcouncil.org — “Rancho Bernardo Inn” View full resource at nationalhealthcouncil.org
Most Recently Shared on March 21, 2012 at 1:15 am By:
Nat. Health Council Health Organization
NHC's 25th Voluntary Health Leadership Conference was possible w/ the support of @npcnow @accintouch @healthcharities http://t.co/BoIgPLhU
AUA Foundation Announces Renewal of the Astellas Rising Stars in Urology Award Program - Yahoo! News
news.yahoo.com — “From Yahoo! News: LINTHICUM, Md., March 15, 2012 /PRNewswire-USNewswire/ -- The American Urological Association (AUA) Foundation is pleased to announce that Astellas U.S. has awarded a $1.2 million independent educational grant to continue its long tradition of supporting outstanding young academic urologists through the AUA Foundation/Astellas Rising Stars in Urology Award program.” View full resource at news.yahoo.com
Most Recently Shared on March 15, 2012 at 3:59 pm By:
Urology & Nephrology OW Health
AUA Foundation Announces Renewal of the Astellas Rising Stars in Urology Award Program: LINTHICUM, Md., March 15... http://t.co/GmaJExjz
Sanofi and Astellas to dissolve sanofi-aventis Yamanouchi Pharmaceutical Inc.
worldpharmanews.com — “World Pharma News - one of the world's leading web-based pharmaceutical news publications - is committed to providing and disseminating the most prominent pharmaceutical news and achievements.” View full resource at worldpharmanews.com
Most Recently Shared on March 1, 2012 at 1:10 pm By:
While GSK & Daiichi were tying up ... RT @OnlyMedics: Sanofi and Astellas to dissolve Yamanouchi J.V. http://t.co/dxguxgzt #pharma
New Class of Treatment for Overactive Bladder Demonstrates Efficacy and Tolerability Across Three Separate Studies | Astellas Pharma Europe Limited | Presseportal.de
presseportal.de — “Astellas Pharma Europe Limited: Paris (ots/PRNewswire) - ASTELLAS PHARMA EUROPE Ltd., European subsidiary of Tokyo-based Astellas Pharma Inc. today announced results from three separate clinical trials that furth” View full resource at presseportal.de
Most Recently Shared on February 24, 2012 at 10:53 am By:
New Class of Treatment for Overactive Bladder Demonstrates Efficacy and Tolerability Across Three Separate Studi... http://t.co/6taOfnSV
Astellas Pharma US Announces Discontinuation of Manufacturing for Amevive | Skin & Aging
skinandaging.com — “Astellas Pharma US Announces Discontinuation of Manufacturing for Amevive | Skin & Aging” View full resource at skinandaging.com
Most Recently Shared on January 6, 2012 at 2:10 pm By:
Skin & Aging Dermatology and Medical Journal
Astellas Pharma US, manufacturer of alefacept (Amevive), has announced its decision to cease sales of Amevive,... http://t.co/2obf8lep
Astellas adds two senior executives at US site | InPharm
inpharm.com — “InPharm.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, jobs, events, and service company listings.” View full resource at inpharm.com
Most Recently Shared on December 5, 2011 at 10:37 am By:
Pharmafocus Health News and Pharma
Astellas adds two senior executives at US site - http://t.co/9ajXPDke
Phase 3 AFFIRM Trial Data of MDV3100 for Advanced Prostate Cancer - MPR
empr.com — “Medivation and Astellas announced positive results from an interim analysis of the Phase 3 AFFIRM trial of MDV3100 in men with advanced prostate cancer previously treated with chemotherapy.” View full resource at empr.com
Most Recently Shared on November 4, 2011 at 6:03 pm By:
Medivation Halts Phase 3 AFFIRM Trial of MDV3100 for Prostate Cancer Following Positive Results http://t.co/TLGyVoBH #ProstateCancer...
A.M. Vitals: Medivation, Astellas Pharma Report Positive Prostate-Drug Results - Health Blog - WSJ
blogs.wsj.com — “Also: FDA approvals up; cooperating with the Chinese to make sure food imports are safe.” View full resource at blogs.wsj.com
Most Recently Shared on November 4, 2011 at 2:57 pm By:
Jason Bellak, MD Doctor, Internist, Physician, and Active Health Library
A.M. Vitals: Medivation, Astellas Pharma Report Positive Prostate-Drug Results via @wsj http://t.co/3rHxc6XO
A.M. Vitals: Medivation, Astellas Pharma Report Positive Prostate-Drug Results - Health Blog - WSJ
blogs.wsj.com — “Also: FDA approvals up; cooperating with the Chinese to make sure food imports are safe.” View full resource at blogs.wsj.com
Most Recently Shared on November 4, 2011 at 1:22 pm By:
A.M. Vitals: Medivation, Astellas Pharma Report Positive Prostate-Drug Results http://t.co/Dvs8yD4i
Astellas abandons oral anticoagulant darexaban | InPharm
inpharm.com — “Astellas Pharma has abandoned the development of its oral direct factor Xa inhibitor darexaban” View full resource at inpharm.com
Most Recently Shared on September 30, 2011 at 8:58 am By:
Pharmafocus Health News and Pharma
Astellas abandons oral anticoagulant darexaban http://ow.ly/6JjMe #pharma
Medical News: Drugmaker Pulls Plug on Oral Anticoagulant - in Cardiovascular, Arrhythmias from MedPage Today
medpagetoday.com — “Astellas Pharma has announced it is shutting down global development of darexaban maleate, a direct factor Xa inhibitor, after an acute coronary syndrome study revealed a higher bleeding risk associat” View full resource at medpagetoday.com
Most Recently Shared on September 29, 2011 at 6:09 pm By:
Drugmaker Pulls Plug on Oral Anticoagulant http://t.co/yCJIpcRV
Astellas -Administration of Seasonal Flu Vaccine ASP7374 Completed in Phase I/II Clinical Trial - Drugs.com MedNews
drugs.com — “From ENP Newswire (September 19, 2011) ENP Newswire - 19 September 2011 Release date- 15092011 - Astellas Pharma Inc. (Headquarters, Tokyo President CEO, Yoshih” View full resource at drugs.com
Most Recently Shared on September 19, 2011 at 1:11 pm By:
Drugs and Devices OW OW Health
Astellas -Administration of Seasonal Flu Vaccine ASP7374 Completed in Phase I/II Clinical Trial: From ENP ... http://t.co/RPHeiWp8 #drug
Advertisement
